Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

Company Overview

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations. The company concentrates on several core therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases and plasma-derived therapies, and maintains an active development pipeline aimed at advancing innovative treatments. In addition to internally discovered assets, Takeda has expanded its capabilities and portfolio through strategic acquisitions that broaden its rare-disease and specialty-care offerings.

Operating globally, Takeda serves patients and healthcare systems across North America, Europe, Asia and other regions through a network of research sites, manufacturing facilities and commercial offices. Leadership is headed by Christophe Weber, who serves as president and chief executive officer and has overseen the company’s transformation into a global specialty biopharma organization. Takeda emphasizes long-term investment in research and development, strategic collaborations, and patient-focused initiatives as central elements of its corporate strategy.

Key Stats

• Today's Range: $16.59 to $16.80
• 50-Day Range: $16.31 to $18.80
• 52-Week Range: $12.99 to $18.90
• Volume: 3.38 million shs
• Average Volume: 2.93 million shs
• Market Capitalization: $53.16 billion
• P/E Ratio: 69.61
• Dividend Yield: 2.99%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Takeda Pharmaceutical Stock Analysis - MarketRank™

Takeda Pharmaceutical scored higher than 20% of companies evaluated by MarketBeat, and ranked 773rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Takeda Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Takeda Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -19.11%

Earnings Growth

Earnings for Takeda Pharmaceutical are expected to decrease by -19.11% in the coming year, from $1.57 to $1.27 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Takeda Pharmaceutical is 69.65, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.37.

Price to Earnings Ratio vs. Sector

The P/E ratio of Takeda Pharmaceutical is 69.65, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.25.

Price to Book Value per Share Ratio

Takeda Pharmaceutical has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TAK.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Takeda Pharmaceutical pays a meaningful dividend of 3.04%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Takeda Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Takeda Pharmaceutical is 208.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 39.37% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.84

News Sentiment

Takeda Pharmaceutical has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Takeda Pharmaceutical this week, compared to 3 articles on an average week.

Search Interest

Only 10 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.04% of the stock of Takeda Pharmaceutical is held by insiders.

Percentage Held by Institutions

9.17% of the stock of Takeda Pharmaceutical is held by institutions.

TAK Stock Analysis - Frequently Asked Questions

How have TAK shares performed this year?

Takeda Pharmaceutical's stock was trading at $15.59 at the beginning of 2026. Since then, TAK shares have increased by 7.3% and is now trading at $16.7250.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co. (NYSE:TAK) announced its earnings results on Friday, January, 30th. The company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.55 by $0.07. The firm earned $7.60 billion during the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical had a trailing twelve-month return on equity of 10.60% and a net margin of 2.58%.
Read the conference call transcript.

Does Takeda Pharmaceutical have any subsidiaries?

Takeda Pharmaceutical subsidiaries include these companies: PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and more.

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's top institutional investors include Bleakley Financial Group LLC (0.01%), QRG Capital Management Inc. (0.01%), Manning & Napier Advisors LLC (0.01%) and Elevation Point Wealth Partners LLC.
View institutional ownership trends.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include Johnson & Johnson (JNJ), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Alibaba Group (BABA), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

• Last Earnings: 1/30/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:TAK
• CIK: 1395064
• Web: www.takeda.com
• Phone: (166) 204-2111
• Fax: 813-3278-2268
• Employees: 47,455
• Year Founded: 1781

Profitability

• EPS (Trailing Twelve Months): $0.24
• Trailing P/E Ratio: 69.61
• Forward P/E Ratio: 10.64
• P/E Growth: N/A
• Net Income: $712.33 million
• Net Margins: 2.58%
• Pretax Margin: N/A
• Return on Equity: 10.60%
• Return on Assets: 5.21%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 1.19
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: $30.09 billion
• Price / Sales: 1.77
• Cash Flow: $3.21 per share
• Price / Cash Flow: 5.21
• Book Value: $14.39 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 3,182,460,000
• Free Float: 3,181,185,000
• Market Cap: $53.16 billion
• Optionable: Optionable
• Beta: -0.06